Restoring regulation – IL-2 therapy in systemic lupus erythematosus

References

• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008.
   PubMed Web of Science ®Google Scholar
• Fujita T, Takaoka C, Matsui H, et al. Structure of the human interleukin 2 gene. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7437–7441.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24–30;302(5906):305–310.
   PubMed Web of Science ®Google Scholar
• Taniguchi T. Structure and function of IL-2 and IL-2 receptors. Behring Inst Mitt. 1992 Apr;91:87–95.
   PubMedGoogle Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–479.
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010 Aug 27;33(2):153–165.
   PubMed Web of Science ®Google Scholar
• Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993 Oct 22;75(2):253–261.
   PubMed Web of Science ®Google Scholar
• Sadlack B, Löhler J, Schorle H, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 1995 Nov;25(11):3053–3059.
   PubMed Web of Science ®Google Scholar
• Klebb G, Autenrieth IB, Haber H, et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol. 1996 Dec;81(3):282–286.
   PubMedGoogle Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6(11):1142–1151.
   PubMed Web of Science ®Google Scholar
• D’Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005 Nov;6(11):1152–1159.
   PubMed Web of Science ®Google Scholar
• Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005 Mar 7;201(5):723–735.
   PubMed Web of Science ®Google Scholar
• Bayer AL, Yu A, Malek TR. Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunology. 2007 Apr 1;178(7):4062–4071.
   PubMed Web of Science ®Google Scholar
• Brandenburg S, Takahashi T, de la Rosa M, et al. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol. 2008 Jun;38(6):1643–1653.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr;6(4):345–352.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994 Mar 23–30;271(12):907–913.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood. 2006 Mar 15;107(6):2409–2414.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunology. 1995 Aug 1;155(3):1151–1164.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003 Apr;4(4):330–336.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Revi Immunol. 2010 Jul;10(7):490–500.
   PubMed Web of Science ®Google Scholar
• Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007 Feb;8(2):191–197.
   PubMed Web of Science ®Google Scholar
• Kim JM, Rudensky A. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev. 2006 Aug;212:86–98.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. T cells and immune tolerance. Cell. 2008 May 30;133(5):775–787.
   PubMed Web of Science ®Google Scholar
• Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010 Jan;11(1):7–13.
   PubMed Web of Science ®Google Scholar
• Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 2011 Oct;10(12):744–755.
   PubMed Web of Science ®Google Scholar
• Humrich JY, Kamradt T, Riemekasten G. Regulatory T cells and rheumatic diseases. Z Rheumatol. 2015 Feb;74(1):26–32.
   PubMed Web of Science ®Google Scholar
• Taams LS, Palmer DB, Akbar AN, et al. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology. 2006 May;118(1):1–9.
   PubMed Web of Science ®Google Scholar
• Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells – ex vivo expansion and therapeutic potential. Semin Immunol. 2006 Apr;18(2):103–110.
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009 May;30(5):656–665.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005 Dec;17(6):638–642.
   PubMed Web of Science ®Google Scholar
• Miyara M, Ito Y, Sakaguchi S. TRE G-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol. 2014 Sep;10(9):543–551.
   PubMed Web of Science ®Google Scholar
• Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunology. 2005 Dec 15;175(12):8392–8400.
   PubMed Web of Science ®Google Scholar
• Suen JL, Li HT, Jong YJ, et al. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology. 2009 Jun;127(2):196–205.
   PubMed Web of Science ®Google Scholar
• Scalapino KJ, Tang Q, Bluestone JA, et al. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunology. 2006 Aug 1;177(3):1451–1459.
   PubMed Web of Science ®Google Scholar
• Humrich JY, Morbach H, Undeutsch R, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):204–209.
   PubMed Web of Science ®Google Scholar
• Bonelli M, von Dalwigk K, Savitskaya A, et al. Foxp 3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis. 2008 May;67(5):664–671.
   PubMed Web of Science ®Google Scholar
• Bonelli M, Savitskaya A, Steiner CW, et al. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunology. 2009 Feb 1;182(3):1689–1695.
   PubMed Web of Science ®Google Scholar
• von Spee-Mayer C, Siegert E, Abdirama D, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2015 Aug;31.
   Google Scholar
• Weigert O, von Spee C, Undeutsch R, et al. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther. 2013;15(1):R35.
   Google Scholar
• Engler JB, Undeutsch R, Kloke L, et al. Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Ann Rheum Dis. 2011 Dec;70(12):2176–2183.
   PubMed Web of Science ®Google Scholar
• Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunology. 2004 Apr 1;172(7):3983–3988.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995 Jun 9;268(5216):1472–1476.
   PubMed Web of Science ®Google Scholar
• Feng Y, Arvey A, Chinen T, et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell. 2014 Aug 14;158(4):749–763.
   PubMed Web of Science ®Google Scholar
• Ballesteros-Tato A, León B, Graf BA, et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity. 2012 May 25;36(5):847–856.
   PubMed Web of Science ®Google Scholar
• Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007 Mar;26(3):371–381.
   PubMed Web of Science ®Google Scholar
• Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008 May;28(5):687–697.
   PubMed Web of Science ®Google Scholar
• Webster KE, Walters S, Kohler RE, et al. In vivo expansion of Treg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009 Apr 13;206(4):751–760.
   PubMed Web of Science ®Google Scholar
• Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010 Aug 30;207(9):1871–1878.
   PubMed Web of Science ®Google Scholar
• Dauphinee MJ, Kipper SB, Wofsy D, et al. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunology. 1981 Dec;127(6):2483–2487.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Murphy ED, Roths JB, et al. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med. 1981 Nov 1;154(5):1671–1680.
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M, Bakke AC, Kitridou RC, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunology. 1983 Jun;130(6):2651–2655.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Ramos JC, Andreu JL, Revilla Y, et al. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature. 1990 Jul 19;346(6281):271–274.
   PubMed Web of Science ®Google Scholar
• Solomou EE, Juang YT, Gourley MF, et al. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunology. 2001 Mar 15;166(6):4216–4222.
   PubMed Web of Science ®Google Scholar
• Tenbrock K, Juang YT, Gourley MF, et al. Antisense cyclic adenosine 5ʹ-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J Immunology. 2002 Oct 15;169(8):4147–4152.
   PubMed Web of Science ®Google Scholar
• Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest. 2005 Apr;115(4):996–1005.
   PubMed Web of Science ®Google Scholar
• Katsiari CG, Tsokos GC. Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmun Rev. 2006 Feb;5(2):118–121.
   PubMed Web of Science ®Google Scholar
• Juang YT, Rauen T, Wang Y, et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J Biol Chem. 2011 Jan 21;286(3):1795–1801.
   PubMed Web of Science ®Google Scholar
• Hedrich CM, Rauen T, Tsokos GC. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J Biol Chem. 2011 Dec 16;286(50):43429–43436.
   PubMed Web of Science ®Google Scholar
• Hedrich CM, Crispin JC, Rauen T, et al. cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16606–16611.
   PubMed Web of Science ®Google Scholar
• Rauen T, Hedrich CM, Tenbrock K, et al. cAMP responsive element modulator: a critical regulator of cytokine production. Trends Mol Med. 2013 Apr;19(4):262–269.
   PubMed Web of Science ®Google Scholar
• Gómez-Martín D, Díaz-Zamudio M, Crispín JC, et al. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun Rev. 2009 Sep;9(1):34–39.
   PubMed Web of Science ®Google Scholar
• Mizui M, Koga T, Lieberman LA, et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunology. 2014 Sep 1;193(5):2168–2177.
   PubMed Web of Science ®Google Scholar
• Ohl K, Wiener A, Schippers A, et al. Interleukin-2 treatment reverses effects of cAMP-responsive element modulator alpha-over-expressing T cells in autoimmune-prone mice. Clin Exp Immunol. 2015 Jul;181(1):76–86.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067–2077.
   PubMed Web of Science ®Google Scholar
• Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 1;365(22):2055–2066.
   PubMed Web of Science ®Google Scholar
• Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood. 2004 May 1;103(9):3428–3430.
   PubMed Web of Science ®Google Scholar
• Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15;106(8):2903–2911.
   PubMed Web of Science ®Google Scholar
• Crispin JC, Alcocer-Varela J. Interleukin-2 and systemic lupus erythematosus – fifteen years later. Lupus. 1998;7(4):214–222.
   PubMed Web of Science ®Google Scholar
• Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes. 2012 Sep;61(9):2340–2348.
   PubMed Web of Science ®Google Scholar
• Long SA, Buckner JH, Greenbaum CJ. IL-2 therapy in type 1 diabetes: ‘trials’ and tribulations. Clin Immunol. 2013 Dec;149(3):324–331.
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48–58.
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Churlaud G, Hartemann A, et al. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes. Curr Diab Rep. 2014 Dec;14(12):553.
   PubMed Web of Science ®Google Scholar
• Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014 Jul;150(7):748–751.
   PubMed Web of Science ®Google Scholar
• Humrich JY, von Spee-Mayer C, Siegert E, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015 Apr;74(4):791–792.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001 May 15;97(10):3146–3151.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 3;5(179):179ra43.
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Revi Immunol. 2015 May;15(5):283–294.
   PubMed Web of Science ®Google Scholar